Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 6/20 | 0.62 |
| ▸ | CASP6 | P55212 | 2/20 | 0.59 |
| ▸ | PLCG1 | P19174 | 4/20 | 0.57 |
| ▸ | PLCB3 | Q01970 | 4/20 | 0.57 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17860358 | 0.91 | PAX8 (0.65) | PAX8CASP6PLCG1PLCB3MALT1 | |
| SCHEMBL17860394 | 0.89 | PAX8 (0.65) | PAX8CASP6PLCG1PLCB3KDM4E | |
| SCHEMBL17860317 | 0.88 | PAX8 (0.64) | PAX8CASP6PLCG1PLCB3KDM4E | |
| SCHEMBL17860363 | 0.88 | PAX8 (0.68) | PAX8CASP6PLCG1PLCB3KDM4E | |
| SCHEMBL17860372 | 0.87 | PAX8 (0.69) | PAX8CASP6PLCG1PLCB3KDM4E | |
| SCHEMBL17860371 | 0.87 | PAX8 (0.67) | PAX8CASP6PLCG1PLCB3 | |
| SCHEMBL17860365 | 0.87 | PAX8 (0.63) | PAX8CASP6PLCG1PLCB3KDM4E | |
| SCHEMBL17860360 | 0.87 | PAX8 (0.67) | PAX8CASP6PLCG1PLCB3MALT1 | |
| SCHEMBL17860453 | 0.87 | PAX8 (0.73) | PAX8CASP6PLCG1PLCB3MALT1 | |
| SCHEMBL17860516 | 0.87 | PAX8 (0.65) | PAX8CASP6PLCG1PLCB3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9526720-B2 | Modulators of hepatic lipoprotein metabolism | THE BROAD INSTITUTE, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9526720-B2 | Modulators of hepatic lipoprotein metabolism | THE BROAD INSTITUTE, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150216855-A1 | Modulators of Hepatic Lipoprotein Metabolism | THE BROAD INSTITUTE, INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150216855-A1 | Modulators of Hepatic Lipoprotein Metabolism | THE BROAD INSTITUTE, INC. | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216855-A1 | Modulators of Hepatic Lipoprotein Metabolism | CETP, LIPC, SLC10A1 | PAX8 4881/4885CASP6 4001/4885PLCG1 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.